Stryker continued its recent buying binge this week, announcing the planned acquisition of Invuity, a manufacturer of lighted instruments for surgeries. Early in the summer, Stryker entered into an agreement to buy the Swiss smoke evacuation device manufacturer SafeAir, and a mere two weeks ago Stryker announced a $1.4 billion deal to snap up K2M Holdings, an emerging player in the area of spinal implants.
Invuity manufacturers a wide range of surgical illumination devices, including retractors, handhelds, and drop-ins. Last month, the company celebrated the commercial launch of PhotonGuide Adapt, a platform with a flexible illuminator and compatible retractors designed especially for surgical gynecologists.
The product line developed by Invuity is dominated by pricey devices, but that hasn’t slowed the company’s growth. Some observers point to Invuity’s success with relatively big-ticket devices as a sign of the quality the company is delivering.
The product line developed by Invuity is dominated by pricey devices, but that hasn’t slowed the company’s growth. Some observers point to Invuity’s success with relatively big-ticket devices as a sign of the quality the company is delivering.
“The only reason Invuity can command this premium pricing despite its small scale is because we believe hospitals and surgeons perceive its products as being differentiated,” Vijay Kumar, an analyst with banking advisory firm Eversore, tells Investor’s Business Daily.
“Invuity’s innovative products in the single-use lighted instrumentation and enhanced energy markets provide best in class illumination and help make surgery safer,” Spencer Stiles, group president of Stryker’s neurotechnology, instruments and spine division, says in a statement. “I look forward to the work we will do together to advance Stryker’s mission of making healthcare better.”
Stryker is expected to spend around $190 million to acquire Invuity. The deal will likely close before the end of the year.